Skip to content

Roberta F. Marback

4 papers in the library · 379 citations · publishing 2018-2022

Papers

Sort Most recent Most cited

Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression

Human Psychopharmacology February 18, 2022 A. P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo et al. 39 citations

Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days...

Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.

Journal of Psychiatric Research May 8, 2021 Rodrigo P Mello, Mariana V F Echegaray, A. P. Jesus-Nunes et al. 22 citations

Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression. We investigated the relationship between trait dissociation and dissociation induced by ketamine and esketamine used as augmentation therapy in treatment-resistant depression (TRD). Adults with TRD were randomly assigned to receive a single intravenous infusion, with...

Intravenous arketamine for treatment-resistant depression: open-label pilot study

European Archives of Psychiatry and Clinical Neuroscience February 20, 2020 Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia-Melo et al. 257 citations

We aimed to analyze the efficacy and safety of arketamine, the R (−)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion...

Comparative study of esketamine and racemic ketamine in treatment-resistant depression

Medicine September 1, 2018 Fernanda S. Correia-Melo, Gustavo C. Leal, Michelle S. Carvalho et al. 61 citations

INTRODUCTION: The use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better...